Exposure to cardiac medication, including ACE inhibitors, β-blockers, and mineralocorticoid receptor antagonists, has been shown to have a significant effect on a wide range of commonly evaluated cardiac outcomes in patients with DMD. Here, NR3C2 is linked to Duchenne muscular dystrophy.